Modulation of the miR-485-3p/PGC-1α Pathway by ASO-Loaded Nanoparticles Attenuates ALS Pathogenesis
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27020615 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von In Soo Ryu und 10 weiteren Autor:innen. Beteiligte Einrichtung: BIORCHESTRA Co., Ltd., 1, Gukjegwahak 2-ro, Yuseong-gu, Daejeon 34000, Republic of Korea. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, MicroRNAs, Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha, Nanoparticles. Die Arbeit nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of SMEs and Startups.
Abstract (Originalsprache)
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by progressive motor neuron degeneration with limited treatment options. In this study, we investigated the pathological role of microRNA-485-3p (miR-485-3p) in ALS, particularly its regulation of PGC-1α, a transcriptional coactivator essential for mitochondrial function and neuroprotection. We also evaluated the therapeutic potential of BMD-001S, a nanoparticle-based formulation encapsulating an antisense oligonucleotide targeting miR-485-3p. Our results demonstrated that miR-485-3p expression was significantly elevated in both SOD1G93A-expressing HMC3 microglial cells and in the spinal cords of SOD1G93A transgenic mice at late disease stages, implicating its contribution to ALS pathogenesis. Intravenous administration of BMD-001S effectively reduced miR-485-3p levels and restored PGC-1α mRNA and PGC-1α protein expression in the spinal cord. These molecular changes were associated with notable therapeutic outcomes, including reduced SOD1 protein aggregation, decreased neuroinflammation, and lower neurofilament light chain concentrations in cerebrospinal fluid. Moreover, BMD-001S treatment was associated with improvements in electrophysiological parameters and preservation of neuromuscular junction integrity during the observation period in SOD1G93A transgenic mice. Taken together, these findings suggest that miR-485-3p/PGC-1α pathway is a promising therapeutic target in ALS and support the potential of BMD-001S as a novel treatment strategy for the disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- BIORCHESTRA Co., Ltd., 1, Gukjegwahak 2-ro, Yuseong-gu, Daejeon 34000, Republic of Korea.
- Department of Neurology, College of Medicine, Hanyang University, 222, Wangsimni-ro, Seongdong-gu, Seoul 04763, Republic of Korea.
- Department of Biomedical Laboratory Science, College of Medical Science, Konyang University, 158 Gwanjeodong-ro, Seo-gu, Daejeon 35365, Republic of Korea.
ORCID-Profile: In Soo Ryu, Seung Hyun Kim, Ilsang Yoon, Hyun-Jeong Cho
Förderung
- Ministry of SMEs and Startups
Zitieren
APA
Ryu, I. S., Ha, D. I., Jung, Y. J., Lee, H. J., Kim, I., Lim, Y. N., Min, H. S., Kim, S. H., Yoon, I., Cho, H. J., & Ryu, J. H. (2026). Modulation of the miR-485-3p/PGC-1α Pathway by ASO-Loaded Nanoparticles Attenuates ALS Pathogenesis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27020615
Vancouver
Ryu IS, Ha DI, Jung YJ, Lee HJ, Kim I, Lim YN, et al. Modulation of the miR-485-3p/PGC-1α Pathway by ASO-Loaded Nanoparticles Attenuates ALS Pathogenesis. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27020615
BibTeX
@article{Ryu2026,
author = {Ryu, In Soo and Ha, Dae-In and Jung, Yeon-Joo and Lee, Hyo Jin and Kim, Insun and Lim, Yu Na and Min, Hyun Su and Kim, Seung Hyun and Yoon, Ilsang and Cho, Hyun-Jeong and Ryu, Jin-Hyeob},
title = {Modulation of the miR-485-3p/PGC-1α Pathway by ASO-Loaded Nanoparticles Attenuates ALS Pathogenesis},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27020615}
}
EUVIMED